You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

CLINICAL TRIALS PROFILE FOR ARBACLOFEN


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Arbaclofen

Trial ID Title Status Sponsor Phase Summary
NCT00557401 ↗ An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD Completed Indivior Inc. Phase 2 To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD
NCT00557401 ↗ An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD Completed XenoPort, Inc. Phase 2 To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD
NCT00788073 ↗ Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome Completed Seaside Therapeutics, Inc. Phase 2 The study objective is to explore the efficacy, safety and tolerability of STX209 for treatment of irritability in subjects with FSX. We hypothesize that STX209 will improve irritability and other typical problem behaviors associated with fragile X syndrome. We also hypothesize that STX209 will be safe and well tolerated.
NCT00817986 ↗ A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms Completed Indivior Inc. Phase 2 The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.
NCT00817986 ↗ A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms Completed XenoPort, Inc. Phase 2 The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Arbaclofen

Condition Name

Condition Name for
Intervention Trials
Multiple Sclerosis 6
Fragile X Syndrome 5
Autism Spectrum Disorder 4
Autism Spectrum Disorders 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Autism Spectrum Disorder 8
Child Development Disorders, Pervasive 7
Autistic Disorder 7
Multiple Sclerosis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Arbaclofen

Trials by Country

Trials by Country for
Location Trials
United States 227
Russian Federation 3
United Kingdom 3
Ukraine 2
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
California 17
Texas 15
North Carolina 14
Washington 13
Arizona 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Arbaclofen

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 11
Phase 2 13
Phase 1 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 17
Terminated 5
Unknown status 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Arbaclofen

Sponsor Name

Sponsor Name for
Sponsor Trials
Seaside Therapeutics, Inc. 10
Indivior Inc. 7
Osmotica Pharmaceutical US LLC 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 27
Other 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.